MRess

MRess is a privately held medical technology company headquartered in London, United Kingdom. The firm was founded in 2018 by Dr. Amelia Rutherford, a former bioinformatics researcher at the University of Oxford, and software engineer Rajesh Patel, who previously worked at a leading clinical data integration startup. MRess focuses on developing advanced analytics platforms for hospitals and research institutions, with the goal of improving clinical decision‑making and accelerating translational research.

The company’s flagship product, MRess Analytics Suite, combines natural language processing, machine learning, and secure data warehousing to extract actionable insights from electronic health records, imaging databases, and genomic sequencing data. Its modules include patient phenotyping, predictive risk scoring, and real‑time clinical trial matching. MRess has a proprietary algorithm that can automatically annotate radiology reports with standardized terminology, reducing the time clinicians spend on manual documentation.

MRess has partnered with more than 50 NHS trust sites and a number of academic research centers across Europe. In 2021, the company secured a £6 million investment from the UK Innovate UK programme, earmarked for expanding its predictive analytics capabilities and scaling its cloud infrastructure. The firm also announced a collaboration with the European Society of Clinical Microbiology and Infectious Diseases to develop a sepsis early‑warning system, which was evaluated in a multi‑centre pilot study reported in the journal Digital Medicine.

Beyond commercial offerings, MRess engages in open‑source initiatives, contributing code to the open‑access OpenEHR framework and publishing monthly white papers on emerging trends in health informatics. The company emphasizes data security and privacy compliance, achieving ISO 27001 certification and adhering to the General Data Protection Regulation (GDPR) for all its operations.

Through its blend of academic rigor and software engineering, MRess is positioned as a key player in the evolving field of precision medicine platforms, aiming to bridge the gap between complex biomedical data and bedside clinical practice.